Financière de Tubize SAの配当利回り
Financière de Tubize SAの配当利回りは何ですか。
Financière de Tubize SAの配当利回りは0.89%です。
配当利回りの定義は何ですか。
配当利回りは、過去1年間の1株当たり配当金と1株の時価での配当金の割合をパーセントで表したものです。
The dividend yield or dividend-price ratio of a share is the dividend per share, divided by the price per share. It is also a company's total annual dividend payments divided by its market capitalization, assuming the number of shares is constant, and is often expressed as a percentage. The reciprocal of the dividend yield is the price-dividend ratio.
A higher dividend yield has been considered to be desirable among many investors. A high dividend yield can be considered to be evidence that a stock is underpriced or that the company has fallen on hard times and future dividends will not be as high as previous ones. Similarly a low dividend yield can be considered evidence that the stock is overpriced or that future dividends might be higher. Some investors may find a higher dividend yield attractive, for instance as an aid to marketing a fund to retail investors, or maybe because they cannot get their hands on the capital, which may be tied up in a trust arrangement. In contrast some investors may find a higher dividend yield unattractive, perhaps because it increases their tax bill.
EURONEXTのセクタHealth Careにおける配当利回りの企業と比べるFinancière de Tubize SA
Financière de Tubize SAは何をしますか。
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Financière de Tubize SAと類似の配当利回り
- Knight-Swift Transportation Incの配当利回りは0.88%です。
- Colgate-Palmolive (India)の配当利回りは0.88%です。
- Pinnacle Investment Managementの配当利回りは0.88%です。
- Symrise AGの配当利回りは0.88%です。
- Pinnacle Partnersの配当利回りは0.88%です。
- Datamatics Global Servicesの配当利回りは0.88%です。
- Financière de Tubize SAの配当利回りは0.89%です。
- Globe Life Incの配当利回りは0.89%です。
- Indo Nationalの配当利回りは0.89%です。
- AFC Ajax NVの配当利回りは0.89%です。
- New York Times Coの配当利回りは0.89%です。
- Enersysの配当利回りは0.89%です。
- AVT Natural Productsの配当利回りは0.89%です。